May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Estrogen Neuroprotection in Anterior Ischemic Optic Neuropathy (AION)
Author Affiliations & Notes
  • N. Moainie
    Ophthalmology, University Of Maryland, Baltimore, MD
  • S.L. Bernstein
    Ophthalmology, University Of Maryland, Baltimore, MD
  • Footnotes
    Commercial Relationships  N. Moainie, None; S.L. Bernstein, None.
  • Footnotes
    Support  NIH RO1–EY015304 HIGHWIRE EXLINK_ID="47:5:4846:1" VALUE="EY015304" TYPEGUESS="GEN" /HIGHWIRE –01
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 4846. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      N. Moainie, S.L. Bernstein; Estrogen Neuroprotection in Anterior Ischemic Optic Neuropathy (AION) . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4846.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : AION, an optic nerve stroke, has an incidence of approximately 1:15,000/yr in the U.S and is the leading cause of sudden optic nerve related vision loss in individuals over 50. While estrogen has been shown to have neuroprotective effects in a number of neuronal damage models, its role in AION is unclear. We used a rodent AION model (rAION) to determine if estrogen exerts a neuroprotective effect on male rats.

Methods: : 10 male Wistar rats were subdivided into two treatment groups: estrogen and control. Estrogen animals received 17–Estradiol (10mg/mL in 60% DMSO/PBS) immediately prior to rAION induction. Control animals received 60% DMSO/PBS vehicle. Following IV rose Bengal, rAION was induced in the OD eye (50mW/13 sec exposure/532nM). The OS eye served as the control. 14d post–induction, animals were stereotactically injected with 3 ul–2% fluorogold into each superior colliculus (SC). 14 days post–SC injection, we euthanized and quantitated retrograde–labeled flat–mounted retinal ganglion cells (RGCs). RGC loss (OD vs OS) was determined using a sterological imaging package (Stereoinvestigator Ver 5.0). Data was then analyzed for statistical significance.

Results: : AION–induced RGC loss was determined for estrogen treated and non–estrogen control animals. Post–rAION RGC–survival was 34.8% for the estrogen treated animals and 30.2% in non–estrogen treated males. Overall RGC numbers in the uninduced eyes were similar for both groups.

Conclusions: : In addition to estrogen’s effectiveness in female rats, there is likely a neuroprotective effect of estrogen against rAION in male rats. Since estrogen controls expression of over 200 genes, the sexual response discrepancy in neuroprotection levels suggests that there may be a graded sexually dimorphic response of estrogen that increases estrogen’s neuroprotective effects in females.

Keywords: neuroprotection • ischemia • cell survival 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.